Observational study of localized angiosarcoma

Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

This study is trying to find the best ways to treat localized angiosarcoma by looking at how patients are managed across different hospitals in Italy.

Quick facts

• Study type: Observational
• Enrollment: 250 (estimated)
• Sex: All
• Sponsor: Italian Sarcoma Group (network)
• Drugs / interventions: radiation
• Locations: 19 sites (Rozzano, Milano and 18 other locations)
• Trial ID: NCT06375941 on ClinicalTrials.gov

What this trial studies

This is a multi-institutional, prospective observational study focusing on patients with localized primary angiosarcoma (AS) across various sites. The study aims to standardize and better define the management of localized AS, particularly regarding the roles of radiation therapy and systemic treatment. By collecting clinical and pathological data from patients treated at reference centers in Italy, the study seeks to address existing gaps in knowledge about treatment approaches and prognostic factors for this rare cancer. The collaboration involves the Italian Sarcoma Group and the Italian Rare Cancer Network to enhance the quality of care for patients with rare tumors.

Who should consider this trial

Good fit: Ideal candidates include individuals of any age with a pathological diagnosis of localized, resectable angiosarcoma.

Not a fit: Patients with non-localized or unresectable angiosarcoma may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment protocols and outcomes for patients with localized angiosarcoma.

How similar studies have performed: While studies on angiosarcoma are limited due to its rarity, similar observational approaches in other rare cancers have shown promise in improving treatment understanding.

Eligibility criteria

Inclusion Criteria:

* pathological diagnosis of AS;
* any site of origin;
* any age;
* primary, localized, resectable disease.

Exclusion Criteria: NA

Where this trial is running

Rozzano, Milano and 18 other locations

• Istituto Clinico Humanitas Research Hospital IRCCS — Rozzano, Milano, Italy (NOT_YET_RECRUITING)
• Centro Riferimento Oncologico CRO — Aviano, Pordenone, Italy (RECRUITING)
• AOU San Luigi Gonzaga — Orbassano, Torino, Italy (RECRUITING)
• Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. — Bari, Italy (NOT_YET_RECRUITING)
• Istituto Ortopedico Rizzoli IOR — Bologna, Italy (RECRUITING)
• Policlinico "Sant'Orsola-Malpighi" — Bologna, Italy (RECRUITING)
• A.O.U. Careggi — Florence, Italy (NOT_YET_RECRUITING)
• Ospedale Policlinico san Martino IRCCS — Genova, Italy (RECRUITING)
• IRCCS Istituto Nazionale Tumori - Milano — Milan, Italy (RECRUITING)
• IRCCS Istituto Europeo di Oncologia — Milan, Italy (NOT_YET_RECRUITING)
• Fondazione Irccs San Gerardo Dei Tintori — Monza, Italy (NOT_YET_RECRUITING)
• Istituto Nazionale Tumori_Fondazione "G.Pascale" — Naples, Italy (RECRUITING)
• IOV Istituto Oncologico Veneto IRCCS — Padova, Italy (RECRUITING)
• Policlinico "Paolo Giaccone" — Palermo, Italy (RECRUITING)
• Nuovo Ospedale di Prato - S. Stefano — Prato, Italy (RECRUITING)
• Fondazione Policlinico Campus Biomedico — Roma, Italy (RECRUITING)
• IRCCS Istituti Fisioterapici Ospitalieri — Roma, Italy (NOT_YET_RECRUITING)
• ASL Ospedale San Giovanni Bosco — Torino, Italy (RECRUITING)
• Ospedale di Trento — Trento, Italy (NOT_YET_RECRUITING)

Study contacts

• Principal investigator: Elena Palassini — IRCCS Istituto nazionale Tumori - Milano
• Study coordinator: Gianluca Ignazzi

Conditions: Angiosarcoma